Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 294

1.

The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.

Bocan TM, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, Major T, Lathia C, Lee H.

Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):70-9.

2.

Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.

Delsing DJ, Offerman EH, van Duyvenvoorde W, van Der Boom H, de Wit EC, Gijbels MJ, van Der Laarse A, Jukema JW, Havekes LM, Princen HM.

Circulation. 2001 Apr 3;103(13):1778-86.

3.

Pharmacology of the ACAT inhibitor avasimibe (CI-1011).

Llaverías G, Laguna JC, Alegret M.

Cardiovasc Drug Rev. 2003 Spring;21(1):33-50. Review.

PMID:
12595916
4.

The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.

Bocan TM, Krause BR, Rosebury WS, Lu X, Dagle C, Bak Mueller S, Auerbach B, Sliskovic DR.

Atherosclerosis. 2001 Jul;157(1):97-105.

PMID:
11427208
5.

Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.

Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.

J Lipid Res. 1999 Jul;40(7):1317-27.

6.

Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.

Worthley SG, Helft G, Corti R, Worthley MI, Chew DP, Fayad ZA, Zaman AG, Fallon JT, Fuster V, Badimon JJ.

Pathophysiol Haemost Thromb. 2007;36(1):9-17. doi: 10.1159/000112634. Epub 2008 Mar 6.

PMID:
18332609
7.

Anti-atherosclerotic properties of the acyl-coenzyme A:cholesterol acyltransferase inhibitor F 12511 in casein-fed New Zealand rabbits.

Rival Y, Junquéro D, Bruniquel F, N'Guyen X, Fauré P, Pomiès JP, Degryse AD, Delhon A.

J Cardiovasc Pharmacol. 2002 Feb;39(2):181-91.

PMID:
11791003
8.

Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.

Junquero D, Oms P, Carilla-Durand E, Autin J, Tarayre J, Degryse A, Patoiseau J, Colpaert FC, Delhon A.

Biochem Pharmacol. 2001 Jan 1;61(1):97-108.

PMID:
11137714
10.

ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits.

Aragane K, Fujinami K, Kojima K, Kusunoki J.

J Lipid Res. 2001 Apr;42(4):480-8.

11.

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.

Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P.

Circulation. 2001 Jan 16;103(2):276-83.

12.

HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.

Bocan TM, Mueller SB, Brown EQ, Lee P, Bocan MJ, Rea T, Pape ME.

Atherosclerosis. 1998 Jul;139(1):21-30.

PMID:
9699888
13.

A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit.

Bocan TM, Rosebury WS, Mueller SB, Kuchera S, Welch K, Daugherty A, Cornicelli JA.

Atherosclerosis. 1998 Feb;136(2):203-16. Erratum in: Atherosclerosis 1998 Jul;139(1):201.

PMID:
9543090
14.
15.

Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits.

Bocan TM, Mueller SB, Brown EQ, Uhlendorf PD, Mazur MJ, Newton RS.

Exp Mol Pathol. 1992 Aug;57(1):70-83.

PMID:
1397193
16.

NTE-122, an acyl-coa:cholesterol acyltransferase inhibitor, prevents the progression of atherogenesis in cholesterol-fed rabbits.

Azuma Y, Date K, Ohno K, Matsushiro S, Nobuhara Y, Yamada T.

Jpn J Pharmacol. 2001 May;86(1):120-3.

17.
19.

Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.

O'Brien PM, Sliskovic DR, Picard JA, Lee HT, Purchase CF 2nd, Roth BD, White AD, Anderson M, Mueller SB, Bocan T, Bousley R, Hamelehle KL, Homan R, Lee P, Krause BR, Reindel JF, Stanfield RL, Turluck D.

J Med Chem. 1996 Jun 7;39(12):2354-66.

PMID:
8691430
20.

HL-004, the ACAT inhibitor, prevents the progression of atherosclerosis in cholesterol-fed rabbits.

Asami Y, Yamagishi I, Murakami S, Araki H, Tsuchida K, Higuchi S.

Life Sci. 1998;62(12):1055-63.

PMID:
9519807

Supplemental Content

Support Center